Source:http://linkedlifedata.com/resource/pubmed/id/18045647
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2008-1-21
|
| pubmed:abstractText |
Previous studies have shown conflicting results on prognostic significance of basal-like breast tumors, but hormone receptor is a confusing factor in most of the prognostic evaluations. We aimed to characterize the prognostic features of basal-like tumors without the influence of hormone receptor status in a series of hormone receptor-negative breast tumors. Using tissue microarray and immunohistochemistry methods, according to the expression of HER2 and basal markers (CK5/6, CK14, EGFR), we categorized 713 consecutive hormone receptor-negative invasive breast cancers into 3 subtypes: HER2 (HER2+), basal-like (HER2-, any basal marker+), and null (HER2-, all basal markers-). The HER2 phenotype was subdivided into pure-HER2 (HER2+, all basal markers-) and basal-HER2 (HER2+, any basal marker+) subgroups. Expression of p53, p63, vimentin, and BRCA1 was assessed immunochemically. Basal-like tumors showed significantly higher grade, more frequent recurrence, and higher expression of vimentin and p63 than HER2 and null phenotypes. Basal-HER2 phenotype had significantly younger mean age and expressed a higher level of p53 and vimentin like basal-like and/or HER2 phenotypes. However, unlike all the other hormone receptor-negative phenotypes, they highly expressed BRCA1. No significant difference was found in 5-year survival among basal-like and the other hormone receptor-negative phenotypes, except for basal-HER2, which showed poorer 5-year overall survival than basal-like tumors. In conclusion, although basal-like breast tumors have distinct clinicopathologic and immunohistochemical features, they have similar 5-year survival compared with the other hormone receptor-negative tumors including HER2 and null phenotypes. However, there exists a small group of hormone receptor-negative tumors expressing HER2 and basal markers simultaneously. This small group of tumors showed significantly poorer 5-year overall survival than basal-like breast tumors and might require different treatment strategy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0046-8177
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
39
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
167-74
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:18045647-Adenocarcinoma,
pubmed-meshheading:18045647-Adult,
pubmed-meshheading:18045647-Aged,
pubmed-meshheading:18045647-Aged, 80 and over,
pubmed-meshheading:18045647-Breast Neoplasms,
pubmed-meshheading:18045647-Female,
pubmed-meshheading:18045647-Fluorescent Antibody Technique, Direct,
pubmed-meshheading:18045647-Humans,
pubmed-meshheading:18045647-Kaplan-Meier Estimate,
pubmed-meshheading:18045647-Middle Aged,
pubmed-meshheading:18045647-Neoplasm Staging,
pubmed-meshheading:18045647-Phenotype,
pubmed-meshheading:18045647-Prognosis,
pubmed-meshheading:18045647-Receptor, erbB-2,
pubmed-meshheading:18045647-Receptors, Estrogen,
pubmed-meshheading:18045647-Receptors, Progesterone,
pubmed-meshheading:18045647-Survival Rate,
pubmed-meshheading:18045647-Tissue Array Analysis,
pubmed-meshheading:18045647-Tumor Markers, Biological
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
|
| pubmed:affiliation |
Department of Pathology, Nanjing Medical University, Nanjing 210029, PR China.
|
| pubmed:publicationType |
Journal Article
|